Literature DB >> 19712042

Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis.

Nelson B Watts1, E Michael Lewiecki, Sydney L Bonnick, Andrew J Laster, Neil Binkley, Robert D Blank, Piet P Geusens, Paul D Miller, Steven M Petak, Robert R Recker, Kenneth G Saag, John Schousboe, Ethel S Siris, John P Bilezikian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19712042     DOI： 10.1359/jbmr.090818

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN： 0884-0431            Impact factor:   6.741


× No keyword cloud information.
  16 in total

1.  The effect of weight and weight change on the long-term precision of spine and hip DXA measurements.

Authors:  R Rajamanohara; J Robinson; J Rymer; R Patel; I Fogelman; G M Blake
Journal:  Osteoporos Int       Date:  2010-08-11       Impact factor: 4.507

2.  Incidence and Predictors of Repeat Bone Mineral Densitometry: A Longitudinal Cohort Study.

Authors:  Emily C White VanGompel; Peter Franks; John A Robbins; Joshua J Fenton
Journal:  J Gen Intern Med       Date:  2017-06-20       Impact factor: 5.128

Review 3.  Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.

Authors:  John T Schousboe; Douglas C Bauer
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

4.  Bone density testing: science, the media, and patient care.

Authors:  Micol S Rothman; Paul D Miller; E Michael Lewiecki; John P Bilezikian
Journal:  Curr Osteoporos Rep       Date:  2014-06       Impact factor: 5.096

5.  Use of pragmatic community-based interventions to enhance recruitment and adherence in a randomized trial of Tai Chi for women with osteopenia: insights from a qualitative substudy.

Authors:  Mary Fischer; Nancy Fugate-Woods; Peter M Wayne
Journal:  Menopause       Date:  2014-11       Impact factor: 2.953

Review 6.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis.

Authors:  S Lekamwasam; J D Adachi; D Agnusdei; J Bilezikian; S Boonen; F Borgström; C Cooper; A Diez Perez; R Eastell; L C Hofbauer; J A Kanis; B L Langdahl; O Lesnyak; R Lorenc; E McCloskey; O D Messina; N Napoli; B Obermayer-Pietsch; S H Ralston; P N Sambrook; S Silverman; M Sosa; J Stepan; G Suppan; D A Wahl; J E Compston
Journal:  Osteoporos Int       Date:  2012-03-21       Impact factor: 4.507

Review 7.  Benefits and limitations of bone mineral density and bone turnover markers to monitor patients treated for osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Curr Osteoporos Rep       Date:  2010-03       Impact factor: 5.096

8.  Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.

Authors:  Itsuo Gorai; Shin Hattori; Yaku Tanaka; Yasuhisa Iwaoki
Journal:  J Bone Miner Metab       Date:  2011-12-02       Impact factor: 2.626

9.  Bone mineral density averaged over a region of interest on femur is affected by age-related change of bone geometry.

Authors:  Y Luo
Journal:  Osteoporos Int       Date:  2018-03-05       Impact factor: 4.507

10.  Characteristics associated with bone mineral density responses to alendronate in men.

Authors:  Erik D Swenson; Karen E Hansen; Andrea N Jones; Zhanhai Li; Brooke Baltz-Ward; Arthur A Schuna; Mary E Elliott
Journal:  Calcif Tissue Int       Date:  2013-03-15       Impact factor: 4.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.